| 1 |
RAPA-501
|
2/3 |
- no placebo
- autologous hybrid TREG/Th2 cells delivered intravenously
- site in MA
|
Rapa Therapeutics LLC |
| 2 |
STRO4
|
2 |
- no placebo
- autologous bone-marrow-derived mesenchymal stem cells delivered intravenously
- site in TX
|
New England Cell Therapeutics, Inc. |
| 3 |
digoxin
|
2 |
- no placebo
- sites in MA, FL
|
Massachusetts General Hospital |
| 4 |
Vit E, N-Ac cysteine, L-cystine, Nicotinamide, Taurursodiol
|
2 |
|
Dallas VA Medical Center |
| 5 |
ranolazine
|
2 |
- placebo controlled trial evaluating two doses of ranolazine
- sites in CA, KS, OH
|
Swathy Chandrashekhar, MBBS |
| 6 |
VHB937
|
2 |
- 33% chance of placebo for 40 weeks followed by an open label extension
- intravenous delivery of an antibody designed to activate TREM2 protein
- sites in CA, FL, GA, KS, MA, NE, NY, OH, TE, TX
|
Novartis Pharmaceuticals |
| 7 |
AMT-162
|
1/2 |
- no placebo
- one-time gene therapy for SOD1-related ALS
- up to five years of follow-up
- sites in CA, MA, NY, MN, FL, GA, KS,PA
|
UniQure Biopharma B.V. |
| 8 |
istradefylline and acute intermittent hypoxia
|
1/2 |
- crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
- sites in FL
|
University of Florida |
| 9 |
prosetin
|
1 |
- placebo controlled trial lasting 14 days followed by open label extension
- oral drug designed to target MAP4 kinase
- site in MA
|
ProJenX |
| 10 |
Psilocybin
|
1 |
|
Johns Hopkins University |
| 11 |
AMX0114
|
1 |
- 25% chance of placebo
- antisense oligoneucleotide not limited to genetic ALS and designed to target calpain 2
- intrathecal delivery of up to 4 doses
- sites in CA, DC, FL, MA, TN, TX, MN
|
Amylyx Pharmaceuticals Inc. |
| 12 |
MN-166 (ibudilast)
|
EAP |
- Expanded Access Programfor people that are not eligible for trials
- Contact WideTrial to join interest list to participate and see additional contact info here
- Site in FL, AZ, MN
|
Mayo Clinic |
| 13 |
RAPA-501
|
EAP |
- Expanded Access Program for people that are not eligible for trials
- Autologous hybrid TREG/Th2 cells delivered intravenously
- sites in AZ, CA, GA, IA, MA, MN, NJ, OR
|
Rapa Therapeutics LLC |